Synthetic cannabinoid receptor agonists (SCRAs) have proliferated as new psychoactive
substances (NPS) over the past decade. Relative to other classes of NPS, SCRAs are …

The cannabinoid receptor subtype 2 (CB2R) represents an interesting and new therapeutic
target for its involvement in the first steps of neurodegeneration as well as in cancer onset …

Indole and indazole synthetic cannabinoids (SCs) featuring l-valinate or l-tert-leucinate
pendant group have recently emerged as prevalent recreational drugs, and their use has …

Synthetic cannabinoid (SC) designer drugs based on indole and indazole scaffolds and
featuring l-valinamide or l-tert-leucinamide side chains are encountered with increasing …

In recent years, many synthetic cannabinoid (CB) receptor agonists have appeared on the
market as constituents of herbal incense mixtures known as “spice”. Contrary to the declared …

The use of cannabis preparations has steadily increased. Although cannabis was
traditionally assumed to only have mild vegetative side effects, it has become evident in …

Synthetic cannabinoids (SC) are the largest class of new psychoactive substances (NPS),
and are increasingly associated with serious adverse effects. The majority of SC NPS are 1 …

Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of new psychoactive
substances (NPS). They commonly comprise N-alkylated indole, indazole, or 7-azaindole …

Up-regulation of CB2R on activated microglial cells, the first step in neurodegeneration, has
been widely demonstrated, and this finding makes the receptor a promising target in the …

Background: Synthetic cannabinoids (SCs) have become an increasing issue in forensic
toxicology. Controlled human studies evaluating pharmacokinetic data of SCs are lacking …